SANTA ANA, Calif., August 6, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 13th […] The post NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid ...
